AnaptysBio, Inc. (ANAB) Price Target Raised to $85.00 at Credit Suisse Group
Other research analysts have also recently issued research reports about the company. Zacks Investment Research raised AnaptysBio from a hold rating to a buy rating and set a $28.00 price target for the company in a research note on Wednesday, August 30th. Stifel Nicolaus reissued a buy rating and issued a $35.00 price target on shares of AnaptysBio in a research note on Tuesday, September 12th. JMP Securities increased their price target on AnaptysBio from $45.00 to $82.00 and gave the stock an outperform rating in a research note on Tuesday. Royal Bank Of Canada initiated coverage on AnaptysBio in a research note on Thursday, September 14th. They issued an outperform rating and a $40.00 price target for the company. Finally, Robert W. Baird initiated coverage on AnaptysBio in a research note on Monday, July 10th. They issued an outperform rating and a $36.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $54.43.
Shares of AnaptysBio (NASDAQ:ANAB) opened at 70.41 on Tuesday. The stock’s market capitalization is $1.43 billion. AnaptysBio has a 12 month low of $15.17 and a 12 month high of $70.48. The firm’s 50 day moving average is $35.88 and its 200 day moving average is $35.88.
AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The business had revenue of $7.00 million during the quarter, compared to the consensus estimate of $3.45 million. On average, equities analysts predict that AnaptysBio will post ($1.98) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/11/anaptysbio-inc-anab-price-target-raised-to-85-00-at-credit-suisse-group.html.
In related news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total transaction of $901,924.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Holdings A/S Novo sold 356,300 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The disclosure for this sale can be found here. Insiders have sold 1,133,940 shares of company stock valued at $24,223,316 in the last ninety days.
A number of hedge funds have recently made changes to their positions in ANAB. Perceptive Advisors LLC bought a new position in AnaptysBio during the first quarter valued at about $24,474,000. Marshall Wace North America L.P. bought a new position in AnaptysBio during the first quarter valued at about $6,924,000. MARSHALL WACE ASIA Ltd bought a new position in AnaptysBio during the first quarter valued at about $6,924,000. Artal Group S.A. boosted its stake in AnaptysBio by 459.4% during the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after buying an additional 205,310 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in AnaptysBio during the first quarter valued at about $3,851,000. 71.35% of the stock is owned by institutional investors and hedge funds.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.